The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Aged ≥ 12 to < 18 years at the time of informed consent/assent signing.
Body weight ≥ 30 kg at both screening and baseline visits.
Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit.
Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits.
Presence of > 20 draining tunnels (fistulas) at either the screening or baseline visit.
Women who are pregnant (or who are considering pregnancy) or breastfeeding.
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
Laboratory values outside of the protocol-defined ranges.